biomedicina slovenica


"Fluorouracil" : 118

  1. Saba Nabil F.; Mody Mayur D.; Tan Elaine S.; Gill Harpaul S.; Rinaldo Alessandra; Takes Robert P.; Strojan Primož; Hartl Dana M.; Vermorken Jan B.; Haigentz Missak; Ferlito Alfio
    Toxicities of systemic agents in squamous cell carcinoma of the head and neck (SCCHN)
    2017
  2. Bonnefoi Herve; Jacot W.; Saghatchian M.; Moldovan C.; Venat-Bouvet L.; Zaman Khurshid; Matos Erika; Petit T.; Bodmer A.; Quenel-Tueux N.; Chakiba C.
    Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer
    2015
  3. Rades Dirk; Strojan Primož; Seidl Daniel; Janssen Stefan; Bajrovic Amira; Kazic Nadja; Hakim Samer G.; Wollenberg Barbara; Schild Steven E.
    Radiochemotherapy for locally advanced squamous cell carcinoma of the head and neck
    2016
  4. Seidl Daniel; Janssen Stefan; Strojan Primož; Bajrovic Amira; Schild Steven E.; Rades Dirk
    Prognostic factors after definitive radio(chemo)therapy of locally advanced head and neck cancer
    2016
  5. Seidl Daniel; Janssen Stefan; Strojan Primož; Hakim Samer G.; Wollenberg Barbara; Schild Steven E.; Rades Dirk
    Importance of chemotherapy and radiation dose after microscopically incomplete resection of stage III/IV head and neck cancer
    2016
  6. Velenik Vaneja; Anderluh Franc; Oblak Irena; Šegedin Barbara; Zakotnik Branko; Strojan Primož
    Preoperative chemoradiation with concurrent capecitabine for locally advanced resectable rectal cance[r] (LARC)
    2008
  7. Oblak Irena; Češnjevar Monika; Anžič Mitja; But Hadžić Jasna; Šečerov Ermenc Ajra; Anderluh Franc; Velenik Vaneja; Jeromen Ana; Korošec Peter
    The impact of anaemia on treatment outcome in patients with squamous cell carcinoma of anal canal and anal margin
    2016
  8. Ocvirk Janja
    Sistemsko zdravljenje raka debelega črevesa in danke
    [Sistemic treatment of colorectal cancer]
    2009
  9. Ocvirk Janja; Reberšek Martina; Škof Erik
    Randomised prospective phase II study of combination chemotherapy epidoxorubicin, cisplatin, 5-FU (ECF) versus epidoxorubicin, cisplatin, capecitabin (ECX) in patients with advanced or metastatic gastric cancer
    2007
  10. Ocvirk Janja; Reberšek Martina; Škof Erik
    Randomised prospective phase II study of combination chemotherapy epidoxorubicin, cisplatin, 5-FU (ECF) versus epidoxorubicin, cisplatin, capecitabin (ECX) in patients with advanced or metastatic gastric cancer
    2007
  11. Slanc Janika; Čufer Tanja; Kozjek Franc; Sonc Monika
    Preliminary study investigating short-term treatment related quality of life in cisplatin and 5-fluorouracil versus etoposide as salvage therapy in metastatic breast cancer patients
    2003
  12. Bossi Paolo; Saba Nabil F.; Vermorken Jan B.; Strojan Primož; Pala Laura; De Bree Remco; Rodrigo Juan Pablo; López Fernando; Hanna Ehab Y.; Haigentz Missak; Takes Robert P.; Slootweg Pieter Johannes; Silver Carl E.; Silver Carl E.; Rinaldo Alessandra; Ferlito Alfio
    The role of systemic therapy in the management of sinonasal cancer
    2015
  13. Ratoša Ivica; Oblak Irena; Anderluh Franc; Velenik Vaneja; But Hadžić Jasna; Šečerov Ermenc Ajra; Jeromen Ana
    Preoperative treatment with radiochemotherapy for locally advanced gastroesophageal junction cancer and unresectable locally advanced gastric cancer
    2015
  14. Kovács Róbert; Csenki Zsolt; Bakos Katalin; Urbányi Béla; Horvath Akos; Garaj-Vrhovac Vera; Gajski Goran; Gerić Marko; Negreira Noelia; Lopez de Alda Miren; Barceló Damià; Heath Ester; Kosjek Tina; Žegura Bojana; Novak Matjaž; Zajc Irena; Baebler Špela; Rotter Ana; Ramšak Živa; Filipič Metka
    Genotoxic effect of 5-fluorouracil in zebrafish after chronic exposure to low doses in a two-generation study
    2014
  15. Čufer Tanja
    Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality
    2014
  16. Strojan Primož; Grašič-Kuhar Cvetka; Žumer Barbara; Kadivec Maksimiljan; Karner Katarina Barbara; Fajdiga Igor; Jančar Boris; Gale Nina; Poljak Mario; Kocjan Boštjan; Zakotnik Branko
    TPF induction chemotherapy and concomitant irradiation with cisplatin and cetuximab in unresectable squamous cell carcinoma of the head and neck
    2014
  17. Grašič-Kuhar Cvetka; Unk Mojca; Strojnik Ksenija; Zakotnik Branko; Fajdiga Igor; Strojan Primož
    Indukcijska kemoterapija z docetakselom, cisplatinom in 5-fluorouracilom pred kemoradioterapijo pri lokalno napredovalih/neoperabilnih karcinomih glave in vratu - izkušnje Onkološkega inštituta Ljubljana
    [Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil before chemotherapy in locally advanced/inoperable head and neck carcinomas - experiences of Institute of Oncology, Ljubljana]
    2012
  18. Ocvirk Janja; Reberšek Martina; Škof Erik; Hlebanja Zvezdana; Boc Marko
    Randomized prospective phase II study to compare the combination chemotherapy regimen epirubicin, cisplatin, and 5-fluorouracil with epirubicin, cisplatin, and capecitabine in patients with advanced or metastatic gastric cancer
    2012
  19. Harbeck Nadia; Čufer Tanja; Borštnar Simona
    Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients
    2013
  20. Ocvirk Janja
    Napredek zdravljenja bolnikov z razsejanim rakom debelega črevesa in danke z vidika internista onkologa
    2013
  21. Grašič-Kuhar Cvetka; Zakotnik Branko
    Weekly docetaxel, cisplatin, and 5-fluorouracil as a palliative chemotherapy for patients with relapsed or metastatic head and neck cancer in poor performance status
    2012
  22. Grašič-Kuhar Cvetka
    Zdravljenje ponovljene ali metastatske bolezni s tedensko kemoterapijo docetaxel/cisplatin/5-fluorouracil (TCF) pri bolnikih s ploščatoceličnim rakom glave in vratu
    2012
  23. Grašič-Kuhar Cvetka; Vogrin Andrej; Zakotnik Branko
    Zdravljenje ponovljene ali metastatske bolezni s tedensko kemoterapijo docetaxel/cisplatin/5-fluorouracil (TCF) pri bolnikih s ploščatoceličnim rakom glave in vratu
    2011
  24. Oblak Irena; Petrič Primož; Anderluh Franc; Velenik Vaneja; Fras Albert-Peter
    Long term outcome after combined modality treatment for anal cancer
    [Dolgoročni rezultati kombiniranega zdravljenja raka analnega kanala]
    2012
  25. Bonnefoi Herve; Piccart Martine; Bogaerts Jan; Čufer Tanja
    TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial
    2011
  26. Gruber G; Cole BF; Castiglione-Gertsch M; Holmberg SB; Lindtner J; Golouh R; Collins J; Crivellari D; Thurlimann B; Simoncini E; Fey MF; Gelber RD; Coates AS; Price KN; Goldhirsch A; Viale G; Gusterson BA; Eržen D; Čufer T; Majdič E; Štabuc B; Lamovec J; Jančar J; Vrhovec I; Kramberger M; Novak J; Naglas M; Senčar M; Červek J; Šebek S; Cerar O; Plesničar A; Zakotnik B
    Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer
    2008
  27. von Minckwitz Gunter; du Bois Andreas; Schmidt Marcus; Maass Nicolai; Čufer Tanja; de Jongh Felix E; Maartense Eduard; Zielinski Christoph; Kaufmann Manfred; Bauer Wolfgang
    Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study
    2009
  28. Piškur Jure; Kolbak Dorthe; Sondergaard Leif; Pedersen Mogens B
    The dominant mutation Suppressor of black indicates that de novo pyrimidine biosynthesis is involved in the Drosophila tan pigmentation pathway
    1993
  29. Piškur Jure; Sondergaard Leif; Gojković Zoran; Stokbro Birgitte; Hjulsager CHarlotte; Davidson Jeffrey; DeMoll Edward; Rawls John; Bahn Erik
    Observed resistance to pyrimidine analogs and sensitivity to uracil in Drosophila is attributed to deregulation of pyrimidine metabolism
    1994
  30. Andersen G; Merico A; Bjornberg O; Andersen B; Schnackerz KD; Dobritzsch D; Piškur J; Compagno C
    Catabolism of pyrimidines in yeast: a tool to understand degradation of anticancer drugs
    2006
  31. Lundgren Stina; Andersen Birgit; Piškur Jure; Dobritzsch Doreen
    Crystallization and preliminary X-ray data analysis of beta-alanine synthase from Drosophila melanogaster
    2007
  32. Viale Giuseppe; Golouh Rastko
    Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer
    2008
  33. Velenik Vaneja
    Kapecitabin kot senzibilizator pri predoperativnem obsevanju bolnikov z lokalno napredovalim resektabilnim rakom danke
    2007
  34. Bohanec-Grabar Petra; Dolžan Vita; Rodriguez-Antona Cristina
    Role of pharmacogenetics for the improvement of cancer tratment
    [Vloga farmakogenetike pri učinkovitejšem zdravljenju raka]
    2007
  35. Pinn Melva E; Austin Laura M; Schomas David A; Miller Robert C
    Case report from Mayo clinic: locally advanced Bartholin gland carcinoma
    [Prikaz primera z Mayo clinic: lokalno napredovali karcinom Bartholinijeve žleze]
    2007
  36. Ocvirk Janja; Reberšek Martina; Velenik Vaneja
    Onkološko zdravljenje bolnikov z rakom debelega črevesa in danke
    [Onkology treatment for patients with colon and rectal cancer]
    2007
  37. Miolo GianMaria; La Mura Nicoletta; Nigri Paola; Murrone Antonio; Da Ronch Laura; Viel Elda; Veronesi Andrea; Lestuzzi Chiara
    The cardiotoxicity of chemotherapy: new prospects for an old problem
    [Kardiotoksičnost kemoterapije. Nove rešitve starega problema]
    2006
  38. Ocvirk Janja
    Zdravljenje bolnikov z rakom debelega črevesa
    [Treatment for patients with colon cancer]
    2006
  39. Gruber Guenther; Bonetti Marco; Nasi Laura M; Price Karen; Castiglione-Gertsch Monica; Rudenstam Carl-Magnus; Holmberg Stig B; Lindtner Jurij; Golouh Rastko; Collins John
    Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from international breast cancer study group trial VI
    2005
  40. Twelves Chris; Wong Alfred; Nowacki Marek P; Abt Markus; Burris Howard; Carrato Alfredo; Cassidy Jim; Cervantes Andres; Fagerberg Jan; Štabuc Borut
    Capecitabine as adjuvant treatment for stage III colon cancer
    2005
  41. Ravnik-Glavač Metka; Berginc Gašper; Potočnik Uroš; Golouh Rastko; Repše Stanislav; Glavač Damjan
    Methodology for molecular genetic screening of microsatellite unstable colorectal cancer and Lynch syndrome
    [Metodologija za molekularnogenetsko presejanje mikrosatelitno nestabilnega kolorektalnega karcinoma in sindroma Lynch]
    2005
  42. Globočnik-Petrovič Mojca; Preskar Andrejka
    Proliferativna vitreoretinopatija
    [Proliferative vitreoretinopathy]
    2005
  43. Ocvirk Janja
    Nov pristop k zdravljenju raka: rak debelega črevesa in danke - pogostnost v svetu in pri nas
    2005
  44. Efficace Fabio; Therasse Patrick; Piccart Martine J; Coens Corneel; van Steen Kristel; Welnicka-Jaskiewicz Marzena; Čufer Tanja; Dyczka Jaroslaw; Lichinitser Michail; Shepherd Lois
    Health-related quality of life parameters as prognostic factors in a nonmestatic breast cancer population: an international multicenter study
    2004
  45. Bohanec Petra; Dolžan Vita
    Genetski polimorfizmi encimov v presnovni poti folata v zdravi slovenski populaciji
    [Genetic polimorphisms of enzymes involved in folate metabolism in healthy Slovenian population]
    2004
  46. Ocvirk Janja
    Sistemsko zdravljenje inoperabilnih jetrnih zasevkov raka debelega črevesa in danke
    2004
  47. Velenik Vaneja; Oblak Irena; Anderluh Franc
    Paliativno zdravljenje raka danke
    2004
  48. Štabuc Borut
    Systemic treatment of colon cancer
    2004
  49. Rogl-Butina Mirjam; Bartenjev Igor
    Nekirurško zdravljenje prekanceroz
    2004
  50. Stojanovič Larisa; Mlakar Boštjan
    Sodobni načini zdravljenja anogenitalnih bradavic
    [Current therapy for anogenital warts]
    2004
  51. Štabuc Borut
    Systemic therapy for colorectal cancer
    2003
  52. Scheithauer W; McKendrick J; Begbie S; Borner M; Burns WI; Burris HA; Cassidy J; Jodrell D; Koralewski P; Štabuc B
    Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial
    2003
  53. Goldhirsch A; Lindtner J; Eržen D; Majdič E; Štabuc B; Plesničar A; Golouh R; Lamovec J; Jančar J; Vrhovec I; Kramberger M
    Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial
    2003
  54. Aebi S; Gelber S; Castiglione-Gertsch M; Gelber RD; Collins J; Thurlimann B; Rudenstam CM; Lindtner J
    Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?
    2000
  55. Colleoni M; Litman HJ; Castiglione-Gertsch M; Sauerbrei W; Gelber RD; Bonetti M; Coates AS; Schumacher M; Bastert G; Lindtner J
    Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF
    2002
  56. Spataro Vito J; Litman Heather; Viale Giuseppe; Maffini Fausto; Masullo Michele; Golouh Rastko; Lindtner Jurij
    Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from international breast cancer study group trial V
    2003
  57. Ocvirk Janja
    Rak žolčnika in žolčevodov - kemoterapija
    [Cancers of gallbladder and biliary tree - chemotherapy]
    2003
  58. Štabuc Borut
    Uracil/tegafur plus oral leucovorin does not affect survival rates but may be better tolerated than standard fluorouracil and leucovorin for previously untreated metastatic colorectal cancer [comment]
    2003
  59. Štabuc Borut
    Recent advances in the systemic therapy of colorectal cancer
    2003
  60. Therasse P; Mauriac L; Welnicka-Jaskiewicz M; Bruning P; Čufer T; Bonnefoi H; Tomiak E; Pritchard KI; Hamilton A; Piccart MJ
    Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study
    2003
  61. Bonnefoi H; Biganzoli L; Mauriac L; Čufer T; Schaefer P; Atalay G; Piccart M
    An EORTC phase I study of capecitabine (xeloda) in combination with fixed doses of cyclophosphamide and epirubicin (cex) as primary treatment for large operable or locally advanced/inflammatory breast cancer
    2003
  62. Štabuc Borut
    Sistemsko zdravljenje raka trebušne slinavke
    [Chemotherapy for pancreatic cancer]
    2002
  63. Awada A; Biganzoli L; Čufer T; Beex L; Lohrisch C; Batter V; Hamilton A; Nooij M; Piccart M
    An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes
    2002
  64. International breast cancer study group J; Eržen D; Majdič E; Štabuc B; Plesničar A; Golouh R; Lamovec J; Jančar J; Vrhovec I; Kramberger M
    Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial
    2002
  65. Colleoni Marco; Gelber Shari; Coates Alan S; Castiglione-Gertsch Monica; Gelber Richard D; Price Karen; Rudenstam Carl-Magnus; Lindtner Jurij; Collins John; Thuerlimann Beat
    Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer
    2001
  66. Bonnefoi H; Biganzoli L; Čufer T; Mauriac L; Hamilton A; Schaefer P; Picart M
    An EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-fu (CEF-infu) as primary treatment of large operable or locally advanced/inflammatory breast cancer
    2001
  67. Zielinski C; Beslija S; Červek J; Mrsič-Krmpotič Z; Tchernozemsky I; Witschke C; Ghilezan N; Grgič M; Jassem J; Tzekova V
    Gemcitabine/Epirubicin/Paclitaxel (GET) vs. 5-Fluorouracil/Epirubicin/Cyclophosphamide (FEC) as first-line treatment in metastatic breast cancer: interim toxicity analysis of a randomised, multicenter phase III trial of the central European cooperative oncology group (CECOG)
    2001
  68. Awada A; Nooij M; Biganzoli L; Čufer T; Beek L; Batter V; Piccart MJ
    A phase I study of continuous infusion 5-fluorouracil (F-intu) in combination with gemcitabine (GEM) in patients (pts) with anthracycline- (A) refractory or A- and taxane- (T) pretreated metastatic breast cancer (MBC)
    2000
  69. Colleoni Marco; Smith Heather; Castiglione-Gertsch Monica; Gelber Richard D; Sauerbrei Willi; Coates Alan S; Schumacher Martin; Bonetti Marco; Bastert Gunter; Lindtner Jurij
    Duration of adjuvant chemotherapy: a joint analysis of two randomized trails investigating 3 versus 6 courses of cyclophosphamide methotrexate and 5-fluorouracil (CMF) without endocrine treatment
    2000
  70. Crivellari Diana; Eržen D; Cerar O; Štabuc B; Golouh R; Lamovec J; Sebek S; Kramberger M; Vrhovec I
    Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII
    2000
  71. Crivellari Diana; Bonetti Marco; Castiglione-Gertsch Monica; Gelber Richard D; Rudenstam Carl-Magnus; Thuerlimann Beat; Price Karen N; Coates Alan S; Huerny Christoph; Lindtner Jurij
    Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International breast cancer study group Trial VII
    2000
  72. Kuhelj Janez
    Prve izkušnje pri zdravljenju kožnih karcinomov z lokalno aplikacijo 5% 5-fluorouracil mazila
    1972
  73. Kolarić K; Potrebica V; Roth A; Stanovnik M
    Controlles phase III clinical study of 4-epi-doxorubicin + 5-fluorouracil vs. 5-fluorouracil alone in gastric and rectosigmoid cancer
    1985
  74. Kolarić K; Potrebica V; Stanovnik M
    Controlled phase III clinical study of 4-epidoxorubicin + 5-fluorouracil versus 5-fluoruracil alone in metastatic gastric and rectosigmoid cancer
    1985
  75. Kolarić K; Potrebica V; Stanovnik M
    Controlled phase III clinical study of 4-epi-doxorubicin + 5-fluorouracil vs. 5-fluorouracil alone in metastatic gastric and rectosygmoid cancer
    1985
  76. Kolarić K; Roth A; Potrebica V; Stanovnik S
    4-epi-doxorubicin + 5-fluorouracil vs 5-fuorouracil alone in advanced gastric cancer - preliminary report of a phase III controlled clinical trial
    1984
  77. Naglas M; Kmetec A
    RANDOMIZED PROSPECTIVE TRIAL COMPARING TWO TREATMENT SCHEDULES OF 5-FLUOROURACIL, METHYL-CCNU, AND VINCRISTINE IN ADVANCED COLORECTAL CANCER
    1980
  78. Pirc B; Naglas M; Červek J; Kmetec A
    KLINIčNI PREIZKUS - SEMUSTIN - NAPREDOVALI RAK KOLONA. (RANDOMIZIRAN PERSPEKTIVNI POSKUS PRIMERJANJA DVEH SHEM ZDRAVLJENJA S 5-FLUOROURACILOM, METHYL-CCNU IN VINKRISTINOM PRI NAPREDOVALNEM RAKU ŠIROKEGA čREVESA IN DANKE)
    1978
  79. Čufer T
    Adjuvant therapy of breast cancer: update
    1999
  80. Štabuc B; Markovič A; Plesničar A; Cizelj TE
    Double modulation of 5-fluorouracil by leucovorin and low-dose methotrexate in advanced colorectal cancer
    2000
  81. Bonnefoi H; Biganzoli L; Čufer T; Hamilton A; Mauriac L; Van Hoorebeeck I; Piccart M
    A feasibility study of epirubicin (E) in combination with cyclophosphamide (C) and infusional 5-fluorouracil (F-infu)(CEF-infu) as primary treatment of large operable (LO) or locally advanced/inflammatory (LA/I) breast cancer (BC)
    1999
  82. Štabuc B
    Chemotherapy of gastrointestinal tumors
    1997
  83. Therasse P; Mauriac L; Welnicka M; Bruning P; Čufer T; Tomiak E; Curran D; Ramirez A; Koopmanschap M; Piccart M
    An EORTC-NCIC-SAKK neoadjuvant randomized phase III study comparing CEF (5FU, epirubicin, cyclophosphamide) vs dose intensified EC+G-CSF (filgrastim) in locally advanced breast cancer (LABC): updated results including quality of life
    1998
  84. Pušnik Dušan
    Trabekulektomija, 5 fluorouracil filtracijska operacija - pol leta izkušenj
    1997
  85. Colleoni M; Price K; Gelber RD; Castiglione-Gertsch M; Rudenstam CM; Coates A; Thuerlimann B; Lindtner J; Collins J; Goldhirsch A
    Dose-response effect of adjuvant cyclophosphamide, methotrexate, fluorouracil in node-positive breast cancer
    1998
  86. Pušnik Dušan
    Trabekulektomija, 5 fluorouracil filtracijska operacija - pol leta izkušenj
    [Trabeculectomia, 5 fluorouracil filtering surgery - 1/2 year follow up]
    1997
  87. Štabuc Borut; Markovič Aleksandra; Brecelj Erik; Bešlija Samir; Cizej Tomaž-Edvard
    Phase II study of fluorouracil, leucovorin and interferon alpha-2a in patients with advanced colon cancer
    [Zdravljenje bolnikov z metastatskim rakom širokega črevesa s fluorouracilom, levkovorinom in interferonom alfa-2a]
    1998
  88. Pendas S; Jaroszeski MJ; Gilbert R; Hyacinthe M; Dang V; Hickey J; Pottinger C; Illingworth P; Heller R
    Direct delivery of chemotherapeutic agents for the treatment of hepatomas and sarcomas in rat models
    [Neposredni vnos kemoterapevtov v celice kot način zdravljenja hepatomov in sarkomov na podganah]
    1998
  89. Grabenbauer Gerhard G; Panzer M; Hueltenschmidt B; Doeker R; Huber K; Kuhne-Velte H J; Hutter M; Ruehl U; Budach V; Wendt T G; et al ;
    Combined radiation and chemotherapy for squamous cell carcinoma of the anal canal: results and prognostic variables in a multiinstitutional series of 173 patients
    1997
  90. Crispino Sergio; Ghezzi P; Ribecco A; Ponticelli P; Lastrucci L; Colombo A; Ardizzoia A; Parmigiani F; Krengli M; Gambaro G; Taino R; Simeone F
    Concomitant radio-chemotherapy for larynx preservation
    1997
  91. Štabuc B
    Sistemsko zdravljenje črevesnega raka
    1996
  92. Marini G; Murray S; Goldhirsch A; Gelber RD; Castiglione-Gertsch M; Price KN; Tattersall MHN; Rudenstam C-M; Collins J; Lindtner J
    The effect of adjuvant prednisone combined with CMF on patterns of relapse and occurence of second malignancies in patients with breast cancer
    1996
  93. Huerny C; Lindtner J; Eržen D; Cerar O; Štabuc B; Golouh R; Lamovec J; Šebek S; Kramberger M; Vrhovec I
    Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer
    1996
  94. Goldhirsch Aron; Gelber Richard D; Castiglione Monica; Price Karen N; Rudenstam Carl-Magnus; Lindtner J; Collins John; Senn Hans-Jorg; Brunner Kurt W; Gallioni Enzo
    Present and future projects of the International breast cancer study group
    1994
  95. Benulič T; Jančar B
    Treatment of advanced esophageal cancer by means of irradiation, cisplatinum and 5-fluorouracil
    1995
  96. Markovič S; Hlebanja Z; Štabuc B
    Postoperative adjuvant chemotherapy with 5-fluorouracyl, adriamycin and cisplatin (FAP) in resectable gastric cancer
    1995
  97. Kolarič K; Bradamante V; Červek J; Cieslinska A; Cisarz-Filipcak E; Denisov LE; Donat D; Drosik K; Gershanovic M; Štabuc B
    A phase II trial of cardioprotection with cardioxane (ICRF-187) in patients with advanced breast cancer receiving 5-fluorouracil, doxorubicin and cyclophosphamide
    1995
  98. Štabuc B
    Sistemsko zdravljenje raka debelega črevesa in danke
    1994
  99. Štabuc B
    Sistemsko zdravljenje črevesnega raka
    1994
  100. Štabuc B
    5-fluorouracil
    1994

1 101  



New search      Comments      Top of page Institute for Biostatistics and Medical Informatics